Life Science Investing Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025
Life Science Investing Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology Congress
Locksley Strengthens U.S. Defense Supply Chain Strategy with Appointment of Lockhead Martin Materials Leader to Advisory Board
FPX Nickel Becomes First Company with British Columbia Exploration Property to Achieve ECOLOGO® Certification, Reinforcing Commitment to Responsible Exploration
